James Lanthier

CEO Mindset Pharma

[James Lanthier @JamesLanthier]

Overheard my 13 year old practicing I wanna be your dog by the Stooges on their guitar. My work is complete.

[James Lanthier @JamesLanthier]

@MindsetPharma now has one of the most clinically advanced next generation psychedelic therapeutics!

https://t.co/KHkBTtAOHa

[The Investors Coliseum @TheInvestorsCo1]

Great piece from cantech letter Mindset Pharma seriously undervalued https://t.co/cmB4YA1hTu
$mset #psychedelics #mentalhealth #mindsetpharma

[James Lanthier @JamesLanthier]

@BillSimmons @TheRewatchables @ChrisRyan77 @SeanFennessey Great choice - thank you!

[James Lanthier @JamesLanthier]

Come join!

[Thomas George @thomasg_grizzle]

Join us tomorrow - Psychedelics 101 🍄 with @Peter_Grinspoon & @JamesLanthier!

https://t.co/dMUgL6tN9j

[James Lanthier @JamesLanthier]

@crockpics Southern Girls! Come on, come on a close second.

[James Lanthier @JamesLanthier]

Just 2 weeks left until my session!

Keep up-to-date with the latest developments in psychedelics research and learn about the clinical path forward.

Register now!

https://t.co/fRcHnre11p

[James Lanthier @JamesLanthier]

@FatherMcKennaa And then there is the novel drug area, where @Mindsetpharma is focused.  Where and how can we make improvements on the known drugs in areas like duration, safety and predictability.

[James Lanthier @JamesLanthier]

@FatherMcKennaa What drugs work best for which indications and is a more personalized model possible, ie do some drugs work better for different people with the same indications.  Intuitively this makes sense but let’s try to understand this via science.

[James Lanthier @JamesLanthier]

@FatherMcKennaa All the way at the other end, we understand that the drugs “work” but HOW do they actually work?

[James Lanthier @JamesLanthier]

@MikeArnoldLaw @MindsetPharma 1014 and 1009 are definitely on the hallucinogenic side. It’s the newer non tryptamine families that show a very interesting and different profile!

[James Lanthier @JamesLanthier]

@MindsetPharma making great progress on advancing non-hallucinogenic drug candidates https://t.co/XSXYHqqdja

[James Lanthier @JamesLanthier]

@Serotonin2arec @semicorporate Agree re promise due to short duration and intensity / nature of experience. There’s just a lot less data on its use. Future of psychedelic medicine hopefully highly personalized and as such there will likely be a place for it / its analogs. But probably not for everyone.

[James Lanthier @JamesLanthier]

@Serotonin2arec @semicorporate Great question and yes I do. TRD made sense as the entry point for clinical study, but the immediacy and (seemingly) low side effect profile will make psychedelics a natural frontline option for MDD

[James Lanthier @JamesLanthier]

@Serotonin2arec @semicorporate the number of drug companies successfully commercializing drugs by themselves from discovery very small. Expertise at every stage of the drug development value chain impossible to recreate in a startup regardless of capitalization IMHO. Right partner is crucial.

[James Lanthier @JamesLanthier]

@Serotonin2arec @semicorporate As great as the non-dilutive funding is, I’ll say what I’ve said in many different forums: getting access to world big pharma expertise in navigating drugs from lead identification through the regulatory process and beyond is an enormous advantage for Mindset

[James Lanthier @JamesLanthier]

@Serotonin2arec @semicorporate @Serotonin2arec that’s right!

[James Lanthier @JamesLanthier]

@Serotonin2arec @MindsetPharma Thanks @Serotonin2arec! Really appreciate your kind words.